VERA Stock Summary and Trading Ideas (Vera Therapeutics - Class A | NASDAQ:VERA)

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Vera Therapeutics - Class A trades on the NASDAQ stock market under the symbol VERA.

As of July 15, 2026, VERA stock price declined to $42.50 with 1,342,554 million shares trading.

VERA has a beta of 0.71, meaning it tends to be less sensitive to market movements. VERA has a correlation of 0.02 to the broad based SPY ETF.

VERA has a market cap of $3.05 billion. This is considered a Mid Cap stock.

In the last 3 years, VERA traded as high as $56.05 and as low as $9.24.

The top ETF exchange traded funds that VERA belongs to (by Net Assets): XBI, IWM, VTI, VXF, IWO.

VERA has outperformed the market in the last year with a return of +83.2%, while the SPY ETF gained +22.5%. However, in the most recent history, VERA shares have underperformed the stock market with its stock returning -2.2% in the last 3 month period and -0.4% for the last 2 week period, while SPY has returned +8.1% and +1.2%, respectively.

VERA support price is $41.24 and resistance is $45.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERA shares will trade within this expected range on the day.